

EMS providers can receive reimbursement when administering monoclonal antibody COVID-19 infusions in the home

To facilitate access to COVID-19 treatment for our members, we're expanding COVID-19 reimbursement to EMS providers administering monoclonal antibody infusions within a member's home. Blue Cross and BCN are following the Centers for Medicare & Medicaid Services' guidelines by covering and paying for these infusions during the COVID-19 public health emergency.

This temporary change is retroactive to the effective date of the code for Blue Cross commercial, Blue Care Network commercial, Medicare Plus BlueSM and BCN AdvantageSM members and is part of the waived member cost share through Sept. 30, 2021 for COVID-19 treatments. For our Medicare Advantage plans, providers should bill Original Medicare for these services.

The following is the list of HCPCS specific and administration codes for COVID-19 monoclonal antibodies that are reimbursable for EMS providers. Ambulance modifiers are **not** needed when submitting claims:

Q0243

M0243 – Injection, casirivimab and imdevimab, 2400 mg (Effective Nov. 21, 2020)

Q0245

M0245 – Injection, bamlanivimab and etesevimab, 2100 mg (Effective Feb. 9, 2021)

M0244 – Intravenous infusion, casirivimab and imdevimab (Effective Nov. 21, 2020)

M0246 – Intravenous infusion, bamlanivimab and etesevimab (Effective Feb. 9, 2021)

M0247 – Intravenous infusion, sotrovimab, includes infusion and post administration monitoring (Effective May 26, 2021)

M0248 – Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency (Effective May 26, 2021)

Q0247 – Injection, sotrovimab, 500 mg (Effective May 26, 2021)

Q0239* – Injection, bamlanivimab-xxxx, 700 mg (Effective Nov. 10, 2020 to April 16, 2021)

M0239* – Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring (Effective Nov. 10, 2020 to April 16, 2021)

For the most current list of billing codes, payment allowances, effective dates and descriptions for currently authorized monoclonal antibody products, see the CMS.gov [Monoclonal Antibody COVID-19 infusion](#)** webpage.

This change has been reflected in the *Temporary changes due to the COVID-19 pandemic* document found on our coronavirus webpage available through Provider Secured Services and on our public website at bcbsm.com/coronavirus (click the *Health Care Providers* tab).

*These codes were effective November 9, 2020 through April 15, 2021.

**Clicking this link means you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're required to let you know we're not responsible for its content.